Lukang Pharmaceutical secures approval for celecoxib raw material

Shandong Lukang Pharmaceutical (SSE:600789) announced that it has received approval from the National Medical Products Administration for its celecoxib chemical raw material listing application. The approved drug, a selective cyclooxygenase-2 inhibitor used as an anti-inflammatory and analgesic, is a chemical raw material intended for pharmaceutical use. As of the announcement, Lukang Pharmaceutical has invested approximately CNY 1,489,900 in the research and development of this drug. According to pharmaceutical market data, the total annual usage of celecoxib raw materials in China was 91.62 tons in 2022 and 109.70 tons in 2023. The company believes the approval will enhance its market competitiveness. The announcement also cautions investors to be aware of market and policy risks that could affect sales.